- Nevro to Report First-Quarter 2024 Financial Results and Host Earnings Conference Call on May 7, 2024
- Nevro Receives FDA 510(k) Clearance to Use SI Fixation System Without Need to Include Lateral Screw
- Nevro Enters Into Cooperation Agreement With Engaged Capital
- Nevro Reports Fourth-Quarter and Full-Year 2023 Financial Results
- Nevro Announces Consensus Statement Supporting High-Frequency (10 kHz) Spinal Cord Stimulation Therapy for Refractory Painful Diabetic Neuropathy
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 12.30 |
---|---|
High | 12.56 |
Low | 12.05 |
Bid | 12.00 |
Offer | 13.41 |
Previous close | 12.32 |
Average volume | 399.89k |
---|---|
Shares outstanding | 36.68m |
Free float | 35.47m |
P/E (TTM) | -- |
Market cap | 451.91m USD |
EPS (TTM) | -2.57 USD |
Data delayed at least 15 minutes, as of Apr 19 2024 21:10 BST.
More ▼